Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 20, 2007, Pages 5610-5613

  Jiang, Wanlong ^a   Tucci, Fabio C ^a   Tran, Joe A ^a   Fleck, Beth A ^a   Wen, Jenny ^a   Markison, Stacy ^a   Marinkovic, Dragan ^a   Chen, Caroline W ^a   Arellano, Melissa ^a   Hoare, Sam R ^a   Johns, Michael ^a   Foster, Alan C ^a   Saunders, John ^a   Chen, Chen ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Antagonist; Cachexia; CYP3A4 enzyme; Lipophilicity; Melanocortin 4 receptor; Pharmacokinetics; Pyrrolidinone

Indexed keywords

2 PYRROLIDONE DERIVATIVE; MELANOCORTIN 4 RECEPTOR; PHENYLALANINEPIPERAZINE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CACHEXIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; IC 50; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALKYLATION; AMINES; ANIMALS; BRAIN; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PYRROLIDINONES; RECEPTOR, MELANOCORTIN, TYPE 4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548563715     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.07.097     Document Type: Article

References (12)

1. Cone R.D. Nat. Neurosci. 8 (2005) 571
2. Scarlett J.M., and Marks D.L. Expert Opin. Investig. Drugs 14 (2005) 1233
3. Foster A.C., Chen C., Markison S., and Marks D.L. IDrugs 8 (2005) 314
4. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., Drabic S.V., Horlick R.A., Lamppu D., Yowe D.L., Balani S., Li P., Zeng H., Joseph I.B., Rodriguez L.E., Maguire M.P., Patane M.A., and Claiborne C.F. J. Med. Chem. 47 (2004) 1602
5. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., and Hofbauer K.G. J. Pharmacol. Exp. Ther. 317 (2006) 771
6. Tucci F.C., White N.S., Markison S., Joppa M., Tran J.A., Fleck B.A., Madan A., Dyck B.P., Parker J., Pontillo J., Arellano L.M., Marinkovic D., Jiang W., Chen C.W., Gogas K.R., Goodfellow V.S., Saunders J., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 15 (2005) 4389
7. Markison S., Foster A.C., Chen C., Brookhart G.B., Hesse A., Hoare S.R., Fleck B.A., Brown B.T., and Marks D.L. Endocrinology 146 (2005) 2766
8. Tran J.A., Tucci F.C., Jiang W., Chen C.W., Markison S., Marinkovic D., Arellano M., White N.S., Pontillo J., Saunders J., Wen J., Madan A., Fleck B.A., Foster A.C., and Chen C. Bioorg. Med. Chem. 15 (2007) 5166
9. Nickolls S.A., Cismowski M.I., Wang X., Wolff M., Conlon P.J., and Maki R.A. J. Pharmacol. Exp. Ther. 304 (2003) 1217
10. Inhibition assays were carried out using microsomes isolated from transfected cells expressing only CYP3A4, and in the presence of the fluorescent substrate BFC. Ketoconazole was used as a positive control.
11. Bakshi R.K., Hong Q., Olson J.T., Ye Z., Sebhat I.K., Weinberg D.H., MacNeil T., Kalyani R.N., Tang R., Martin W.J., Strack A., McGowan E., Tamvakopoulos C., Miller R.R., Stearns R.A., Tang W., Maclntyre D.E., van der Ploeg L.H., Patchett A.A., and Nargund R.P. Bioorg. Med. Chem. Lett. 15 (2005) 3430
12. Konturek S.J., Konturek J.W., Pawlik T., and Brzozowski T. J. Physiol. Pharmacol. 55 (2004) 137